Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
China
Biotech
Henlius pens $202M pact for HanchorBio's midstage CD47 blocker
Fosun Pharma subsidiary Henlius Biotech is paying $10 million upfront for regional rights to HanchorBio’s phase 2 CD47 blocker.
James Waldron
Jul 1, 2025 3:50am
Alphabet's Calico weaves anti-aging deal with China's Mabwell
Jun 26, 2025 4:52pm
Fierce Pharma
Vor Bio's surprise $4B revival deal splits investor reactions
Jun 26, 2025 10:55am
Arbutus regains China rights to potential hep B cure from Qilu
Jun 25, 2025 9:15am
MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b
Jun 24, 2025 10:06am
Corxel, Sciwind post data as China's obesity push gathers pace
Jun 23, 2025 9:20am
